[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643056":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":18,"centralContacts":19,"locations":30,"responsibleParty":45,"collaborators":18,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":49,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":18,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":70,"whyStopped":18,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":80},{"fullName":5,"class":6},"CHU de Reims","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"Patients with juvenile idiopathic arthritis","Single group of adolescents and adults with juvenile idiopathic arthritis undergoing a standardized sarcopenia screening assessment at inclusion.",[12],"Other: Sarcopenia screening assessment",[14],{"type":6,"name":15,"description":16,"armGroupLabels":17,"otherNames":18},"Sarcopenia screening assessment","Participants will undergo a standardized single-visit assessment including hand grip strength measurement, whole-body DEXA scan for body composition, validated questionnaires, and collection of socio-demographic and clinical data from medical records.",[9],null,[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Ambre HITTINGER-ROUX","CONTACT","03 10 73 67 07","0033","ahittinger-roux@chu-reims.fr",{"name":27,"role":22,"phone":28,"phoneExt":24,"email":29},"Jean-Hugues SALMON","03 26 78 44 21","jhsalmon@chu-reims.fr",[31],{"facility":32,"status":18,"city":33,"state":18,"zip":18,"country":34,"countryCode":35,"cosmosGeoPoint":36,"geoPoint":41,"contacts":42},"Marie Muller","Reims","France","FR",{"type":37,"coordinates":38},"Point",[39,40],4.02853,49.26526,{"lat":40,"lon":39},[43,44],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},{"name":27,"role":22,"phone":28,"phoneExt":24,"email":29},{"type":46,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100643056","sarcopenia-and-juvenile-idiopathic-arthritis-100643056",false,"NCT07634354","Sarcopenia and Juvenile Idiopathic Arthritis","Prevalence Study of Sarcopenia in Juvenile Idiopathic Arthritis","SAJI","inclusion criteria :\n\n* Patients followed in French hospitals participating in the study for juvenile idiopathic arthritis, all forms combined, diagnosed according to the ILAR criteria defined in Edmonton in 2001\n* Patients aged 15 to 40 years\n* Affiliated to social security\n* Agreeing to participate in the study and having given their written consent (signed consent form).\n\nIn the case of a minor patient, the consent of the patient and their legal guardians is required.\n\nexclusion criteria :\n\n* Patient under legal guardianship\n* Patient not covered by social security\n* Pregnant woman\n* Inability to perform a functional test required by the study (grip test or whole-body DEXA scan)\n* Inability to understand the questionnaires","ALL","15 Years","40 Years",{"count":59,"type":60},200,"ESTIMATED","INTERVENTIONAL",[63],"NA","Juvenile idiopathic arthritis (JIA) is a rare chronic inflammatory rheumatic disease that begins during childhood and may persist into adulthood in many patients. In addition to joint pain, swelling, and long-term articular damage, chronic inflammatory diseases may also be associated with early sarcopenia, defined as a loss of muscle strength and muscle mass. While this association has been described in adult inflammatory rheumatic diseases, it has not been well studied in patients with JIA.\n\nThe aim of this study is to screen for sarcopenia in adolescents and adults with JIA in France. Sarcopenia will be assessed using validated questionnaires, hand grip strength measured with a Jamar dynamometer, and body composition measured by dual-energy X-ray absorptiometry (DEXA). Completion of validated questionnaires will assess nutritional status, fatigue, physical activity, and functional impact. Socio-demographic and clinical data will also be collected from medical records.\n\nThis multicenter cross-sectional study will be conducted between June 2026 and October 2027 in 11 French hospitals. Eligible participants are patients aged 15 to 40 years with JIA diagnosed according to ILAR criteria and followed in a French hospital.\n\nThis study will provide the first estimate of sarcopenia prevalence among patients with JIA in France. It will also help identify factors associated with sarcopenia and its impact on daily functioning and quality of life. In the longer term, the findings may help clinicians better identify patients at risk and support earlier management focused on disease control, physical activity, and nutritional care.",[66],"Juvenile Idiopathic Arthritis",[68,69],"Juvenile idiopathic arthritis","Sarcopenia","NOT_YET_RECRUITING","2026-06-03",{"date":73,"type":74},"2026-06-08","ACTUAL",{"date":76,"type":60},"2026-06",{"date":78,"type":60},"2027-10",{"name":5,"class":6},1]